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HD LC A B C
We confirmed, using standardised thrombin
generation assays a prothrombotic state in
patients with liver cirrhosis (TM-mediated
inhibition represents the activity of the
protein C/S system)
We demonstrated that this prothrombotic
state is visible already in absence of
thrombomodulin (velocity index represents
the burst of thrombin generation)
We demonstrated that classical biomarkers
used to assess the bleeding risk in patients
with liver cirrhosis are inadequate
In liver cirrhosis, a prolonged PT / aPTT is associated with a prothrombotic coagulation profile
A/B/C, Child-Pugh A/B/C; aPTT, activated partial thromboplastin time; HD, healthy
donors; LC, liver cirrhosis; PT, prothrombin time; TM, thrombomodulin; VI, velocity index
Highlights Lay summary
 Patients with cirrhosis display a prothrombotic
coagulation profile.
 This is due to a relative decrease of natural anti-
coagulants compared with procoagulants.
 In cirrhosis, PT and aPTT correlate with a pro-
thrombotic state, and are inadequate as bleeding
risk biomarkers.https://doi.org/10.1016/j.jhepr.2020.100120We demonstrate that the laboratory parameters used
to assess bleeding risk of patients with liver disease,
e.g. prothrombin time/international normalised ratio
(PT/INR) and activated partial thromboplastin time
(aPTT), are inadequate for this purpose because they
are correlated with a prothrombotic coagulation pro-
file. In this article, we highlight the need for alterna-
tive parameters to assess bleeding risk in patients
with liver disease.
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Background & Aims: Different liver dysfunction biomarkers are used to assess the bleeding risk of patients with cirrhosis,
either as such or included in bleeding risk assessment scores. Since the current model of coagulation in patients with cirrhosis
describes a procoagulant tendency with increasing severity according to Child-Pugh stage, we decided to investigate the
relation between liver dysfunction biomarkers and thrombin generation. Our aim was to verify their adequacy for bleeding
risk assessment.
Methods: We performed a prospective single-centre study including 260 patients with liver cirrhosis. Thrombin generation
was measured using ST Genesia® Thrombin Generation Systemwithout and with thrombomodulin in order to assess the role
of proteins C and S. Relations between thrombin generation and Child-Pugh/model for end-stage liver disease (MELD) scores,
prothrombin time (PT)/international normalised ratio (INR), activated partial thromboplastin time (aPTT), factor V activity,
albumin, and total bilirubin were assessed.
Results: Thrombomodulin-mediated inhibition of thrombin generation was significantly decreased in patients with liver
cirrhosis compared with healthy donors (p <0.0001) and in Child-Pugh B and C compared with A (p <0.0001 [A–B], 0.4515 [B–
C], <0.0001 [A–C]). Thrombomodulin-mediated inhibition significantly decreased with increasing PT/INR, aPTT, and total
bilirubin levels and with decreasing factor V activity and albumin levels.
Conclusions: Worsening liver dysfunction biomarkers reflect an increasing prothrombotic profile in patients with liver
cirrhosis. In particular, prolonged PT/INR and aPTT as well as decreasing factor V activity are related to an increasing
thrombotic risk and not to an increasing bleeding risk. These parameters should not be used to assess bleeding risk due to
haemostatic anomalies in patients with liver cirrhosis. Alternative biomarkers for bleeding risk assessment in patients with
liver cirrhosis need to be developed.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
For a long time, patients with liver cirrhosis were considered to
have a bleeding diathesis. This was due to prolonged routine
coagulation assays, i.e. prothrombin time (PT)/international
normalised ratio (INR) and activated partial thromboplastin time
(aPTT). However, in the last 2 decades, in vitro evidence has
accumulated in favour of a procoagulant shift in patients with
liver cirrhosis.1–7 Indeed, the coagulopathy of liver cirrhosis isKeywords: Liver cirrhosis; Thrombosis; Blood coagulation tests; Serum albumin;
Bilirubin; Coagulation.
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changes. The main prohaemorrhagic changes include decreased
coagulation factors (with the exception of factor VIII) and
possible dysfibrinogenemia. The main prothrombotic changes
include increased factor VIII and decreased natural anticoagu-
lants, i.e. proteins C/S and antithrombin.8 Routine coagulation
assays, such as PT or aPTT, are not sensitive to the changes
occurring in natural anticoagulants and they only assess the
reduced levels of coagulation factors. In contrast, thrombin
generation assays without and with thrombomodulin (TM) or
Protac®, as protein C activators, can evaluate both prohaemor-
rhagic and prothrombotic changes. These assays showed an
increased endogenous thrombin potential (ETP) when using
TM,4,5,7 an increased ratio of ETP with and without TM or Pro-
tac,2,3,5–7 and an increased velocity index7 in patients with liver
cirrhosis compared with normal subjects. These characteristics
have been shown to be markers of thrombotic risk in patients
Research articlewith cirrhosis9 as well as in other populations.10–12 Therefore,
in vitro analyses showed that patients with liver cirrhosis
generally display a prothrombotic coagulation state, an obser-
vation that is in line with recent clinical studies.13
This prothrombotic state seems to increase with the severity
of liver dysfunction assessed by Child-Pugh2,5 or MELD scores4,6
(which include PT/INR), but also with increasing INR.7 However,
in clinical settings, patients with liver cirrhosis are still broadly
considered as having a bleeding diathesis, and increasing PT/INR
and aPTT continue to be widely used as bleeding risk assessment
parameters in patients with liver cirrhosis.14,15 Moreover, several
bleeding risk assessment scores include an abnormal liver
function, which is differently defined by the various scores:
increasing PT/INR,16 biochemical evidence of liver dysfunction
(HAS-BLED score; liver cirrhosis or increased bilirubin and
transaminases)17 or not specified (HEMORR2AGES score).18 This
contradicts the accumulating evidence of a procoagulant
profile in patients with liver cirrhosis, which worsens in parallel
to cirrhosis severity. However, to date, there are no published
data regarding the alteration of the haemostatic potential of
patients with liver cirrhosis depending on liver dysfunction
biomarkers, including PT/INR, aPTT, factor V, albumin, and total
bilirubin.
In this study, we aimed to assess the relation between liver
cirrhosis stage, liver dysfunction biomarkers, and thrombin
generation. This should determine the adequacy of these bio-
markers for bleeding risk assessment.Patients and methods
Study design
We performed a prospective single-centre study at the Division
of Haematology and Central Haematology Laboratory as well as
at the Division of Gastroenterology and Hepatology, Lausanne
University Hospital (CHUV), Lausanne, Switzerland.Patients and study procedure
We prospectively included 260 patients older than 18 years with
a diagnosis of liver cirrhosis Child-Pugh A–C of any aetiology as
assessed by experienced gastroenterologists and hepatologists,
between 22 January 2019 and 29 February 2020. Pregnant
women, patients under anticoagulation, and patients unable to
provide informed consent were excluded. Of note, patients with
a history of splanchnic vein thrombosis and other venous
thromboembolic events or cancer were not excluded. Additional
blood was drawn during routine blood collection. Blood for
thrombin generation assay was drawn into S-Monovettes®
(Sarstedt AG & Co. KG, Nümbrecht, Germany) containing 0.106
mmol/L trisodium citrate as anticoagulant. Platelet-free plasma
(PFP) was obtained by double centrifugation at 1,800× g for 10
min and immediately stored at −80C. The following liver
dysfunction biomarkers were analysed: PT, INR, aPTT, factor V
activity, total bilirubin, and albumin.
We included 59 healthy donors, who had been recruited for
the internal validation of ST Genesia® Thrombin Generation
System (Stago, Asnières-sur-Seine, France). The project was
presented to the patients during a scheduled routine control by
the treating hepatologists. Clinical data of interest were filled in a
standardised questionnaire by the physician in charge.
Patients who were included in this study gave their written
informed consent. The study was approved by the local EthicalJHEP Reports 2020Committee (protocol CER-VD 2018-02157) and conducted ac-
cording to the Declaration of Helsinki.19
Laboratory assays
PT/INR, aPTT, and factor V activity were analysed on a Sysmex
CS5100 coagulation analyser (Siemens Healthcare, Erlangen,
Germany) with the following reagents: Dade®-Innovin®,
Pathromtin SL, human standard plasma, factor V deficient
plasma, and calcium chloride (Siemens Healthcare).
Albumin and total bilirubin levels were analysed on a Cobas
8000 (RocheDiagnostics International Ltd, Rotkreuz, Switzerland)
using Albumin Gen. 2 (Roche Diagnostics International Ltd) and
Bilirubin Total Gen. 3 (Roche Diagnostics International Ltd),
respectively.
Automated thrombin generation assay
Thrombin generation was analysed using the ST Genesia®
Thrombin Generation System according to the manufacturer
instructions. Analyses were performed on thawed citrated PFP.
PFP was thawed for 10 min in a water bath at 37C. Calibration
was performed every day to correct for the inner filter effect, the
effect of a2-macroglobulin, and the substrate consumption.20
FluoSet (Stago) was used for plasma-specific calibration for
colour. The initiator (ThromboScreen [Stago; intermediate tissue
factor concentration] with and without TM) was automatically
added to plasma and incubated for 10 min. After this incubation,
the coagulation was triggered by the automatic addition of
FluoStart (Stago) and the measurement was started. Analyses
were performed without and with TM in duplicate. Corn trypsin
inhibitor was not used as inhibitor of contact activation because
the tissue factor concentration was >1 pM.21–23
The following parameters without and with TM were
measured: time until thrombin generation (lag time, min),
maximal concentration of thrombin (peak heightwithout TM, peak
heightwith TM, nM), thrombin generation velocity (velocity
indexwithout TM, velocity indexwith TM, nM/min), and area under
the curve for total thrombin generation (ETPwithout TM, ETPwith TM,
nM min). The software calculated the TM-mediated inhibition
as follows:
ETPwithout TM − ETPwith TM
ETPwithout TM
For the other parameters, we calculated ratios of values with
and without TM (TM ratios).
Normalisation of the results using a reference plasma
(RefPlasma) was performed by the ST Genesia software.
TM-mediated inhibition is the most frequently used param-
eter in the literature for patients with liver cirrhosis and the most
interesting one in case of protein C/S-system disturbances. The
velocity indexwithout TM showed a prothrombotic haemostatic
profile in patients with liver cirrhosis already without TM7 and
therefore reflects prothrombotic changes that are independent of
the protein C/S system.
Statistics
Comparisons of thrombin generation parameters (ETPwithout TM,
ETPwith TM, TM-mediated inhibition, peak heightwithout TM, peak
heightwith TM, velocity indexwithout TM, velocity indexwith TM, and
TM ratios for the peak height and the velocity index) between
healthy donors and patients with liver cirrhosis were assessed
graphically and compared using t tests for parameters with2vol. 2 j 100120
Table 1. Clinical and laboratory characteristics of healthy donors and
patients.




cirrhosis (n = 260)
Age, years 34 (19–63) 58 (18–81)
Sex
Male 33 (55.9) 209 (80.7)
Female 26 (44.1) 51 (19.6)
BMI, kg/m2 n.a. 27.7 (14.5–46.7)
Cancer n.a. 50 (19.2)
Hepatocellular carcinoma n.a. 41
Child-Pugh A n.a. 33 (16)
Child-Pugh B n.a. 5 (10)












Other VTE events n.a. 8 (3.1%)
Aetiology
Alcohol n.a. 89 (34.2)
Viral hepatitis n.a. 53 (20.4)
HCV n.a. 37 (14.2)
HBV n.a. 14 (5.4)
Combined (HBV + HCV) n.a. 2 (0.8)
Alcohol + NASH n.a. 41 (15.8)
Alcohol + viral hepatitis n.a. 22 (8.5)




Alcohol + NASH + viral
hepatitis
n.a. 8 (3.1)
NASH + viral hepatitis n.a. 3 (1.2)
Child–Pugh n.a. 5.9 (5–12)
A n.a. 200 (77.0)
B n.a. 47 (18.1)
C n.a. 13 (5)
MELD score n.a. 9.7 (6–29)
MELD-Na score n.a. 10.7 (6–30)




Prothrombin time, % n.a. 77.2 (34.0–120.0)
INR n.a. 1.2 (1.0–2.0)
aPTT, seconds n.a. 35.0 (25.0–62.0)
Factor V activity, % n.a. 81.3 (23–185)
Albumin, g/L n.a. 40.4 (18.0–57.0)
Total bilirubin, lmol/L n.a. 23.6 (3.0–382)
Fibrinogen, g/L n.a. 2.7 (0.9–9.1)
Thrombin generation
Lag timewithout TM, min 2.4 (1.7–3.7) 2.3 (1.0–5.8)
Lag timewithout TM norm., ratio 1.4 (0.7–1.9) 1.2 (0.6–3.0)
Lag timewith TM, min 2.7 (1.8–4.2) 2.6 (1.1–7.2)
Peak heightwithout TM, nM 200.0 (85.2–339.2) 219.6 (73.1–395.1)
Peak heightwithout TM norm., % 72.4 (31.5–120.5) 74.3 (22.5–127.1)
Peak heightwith TM, nM 136.5 (31.1–291.0) 164.8 (21.0–325.2)
Time to peakwithout TM, min 5.2 (3.8–7.7) 4.5 (2.6–10.0)
Time to peakwithout TM norm.,
ratio
1.2 (0.9–1.8) 1.2 (0.6–2.4)
Time to peakwith TM, min 4.5 (3.4–6.8) 4.4 (2.8–10.3)
Velocity indexwithout TM,
nM/min
105.0 (32.7–230.1) 156.4 (26.0–440.0)
Velocity indexwithout TM,
norm., %
66.3 (21.3–149.7) 84.6 (13.2–266.4)
(continued on next page)
Table 1 (continued)




cirrhosis (n = 260)
Velocity indexwith TM, nM/min 107.8 (13.7–261.7) 137.9 (8.3–351.9)
ETPwithout TM, nM min 1,231 (655–2029) 1,168 (450–1892)
ETPwithout TM norm., % 81.2 (43.4–125.4) 76.5 (28.0–127.5)
ETPwith TM, nM min 586 (165–1528) 742 (123–1483)
TM–mediated
inhibition, %
53.7 (24.7–85.9) 36.4 (0.0–88.6)
aPTT, activated partial thromboplastin time; ETP, endogenous thrombin potential;
INR, international normalised ratio; MELD, model for end-stage liver disease; n.a., not
applicable or not available; NASH, non-alcoholic steatohepatitis; norm., normalised;
TM, thrombomodulin; VTE, venous thromboembolism.
JHEP Reports 2020normal distribution (ETPwithout TM normalised, peak heightwithout
TM normalised). For parameters with non-normal distribution,
the Mann-Whitney test was used (ETPwithout TM, ETPwith TM,
TM-mediated inhibition, peak heightwithout TM, peak heightwith
TM, peak height ratio, velocity indexwithout TM, velocity index-
without TM normalised, velocity indexwith TM, velocity index ratio).
Comparisons between healthy donors and Child-Pugh categories
were done using Kruskall-Wallis tests with multiple compari-
sons. For the MELD score and liver dysfunction biomarkers, we
chose to analyse absolute and normalised ETPwithout TM, absolute
and normalised velocity indexwithout TM, as well as TM-mediated
inhibition (see above). Relations between MELD score and
thrombin generation parameters were assessed graphically and
fitted using linear regressions. Relations between PT, aPTT, factor
V activity, albumin and total bilirubin and thrombin generation
parameters were assessed graphically and fitted using linear
regression or quadratic function as required. All statistical ana-
lyses were performed using GraphPad Prism 8.0.1 (GraphPad
Software, San Diego, CA).
Results
Patient characteristics including age, sex, liver cirrhosis aetiology,
and severity of liver dysfunction as well as results of routine
laboratory tests and thrombin generation parameters are given
in Table 1, which also includes the characteristics of the healthy
donors.
Thrombin generation according to Child-Pugh score
Results of thrombin generation assays are presented in Table 1
and Fig. 1. The ETPwithout TM was slightly but significantly
reduced in patients with liver cirrhosis compared with healthy
donors (1172 ± 240 [median ± standard deviation] nM min vs.
1227 ± 233 nM min; p = 0.0487) (Fig. 1A). A trend towards a
decrease of ETPwithout TM with increasing Child-Pugh score was
observed but reached significance only when comparing Child-
Pugh A with C (1198 ± 230 nM min [A] vs. 1065 ± 208 nM min
[B] vs. 972 ± 333 nM min [C]; p = 0.0509, >0.9999 and 0.0233
[A vs. B, B vs. C, and A vs. C, respectively]). When normalised,
ETPwithout TM significantly decreased from Child-Pugh A to B and
from B to C (78.7 ± 15.0 % [A] vs. 68.5 ± 12.3 % [B] vs. 63.8 ± 20.2 %
[C]; p = 0.0232, 0.5928, and 0.0034 [A vs. B, B vs. C and A vs. C,
respectively] [Fig. 1B]). With TM, ETP was significantly increased
in patients with liver cirrhosis compared with healthy donors (752
± 287 nM min vs. 583 ± 268 nM min; p <0.0001) and signifi-
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Fig. 1. Thrombin generation in healthy individuals and patients with liver cirrhosis. Thrombin generation parameters in healthy donors, patients with liver
cirrhosis, and according to Child-Pugh stage (A/B/C). Results of t test, Mann-Whitney test, and ANOVA with multiple comparisons, or Kruskall-Wallis tests with
multiple comparisons. Error bars represent mean and standard error. *p = 0.01-0.05, **p = 0.001–0.0099, ***p = 0.0001–0.00099, ****p <0.0001. ETP, endogenous
thrombin potential; HD, healthy donors; NORM., normalised; PH, peak height; TM, thrombomodulin; VI, velocity index.
Research articlepatients (865 ± 245 nM min vs. 691 ± 289 nM min; p = 0.0010)
(Fig. 1C). This resulted in a significant decrease of TM-mediated
inhibition (Fig. 1D) in patients with liver cirrhosis compared
with healthy donors (33.8 ± 21.8 % vs. 53.7 ± 15.6 %; p <0.0001)
and a significant decrease of TM-mediated inhibition in Child-
Pugh B and C compared with A (40.5 ± 20.2 % [A] vs. 14.9 ±
17.1 % [B] vs. 6.9 ± 9.5 % [C]; p <0.0001, 0.4515 and <0.0001 [A vs.
B, B vs. C, and A vs. C, respectively]).
The peak heightwithout TM was significantly increased in pa-
tients with liver cirrhosis compared with healthy donors (224.9 ±
59.7 nM vs.193.6 ± 59.3 nM; p = 0.0127). However, it significantly
decreased from Child-Pugh A to C (229.3 ± 61.1 nM [A] vs. 201.3 ±
49.0 nM [B] vs. 173.9 ± 58.9 nM [C]; p = 0.9706, 0.4936 and
0.0422 [A vs. B, B vs. C, and A vs. C, respectively]) (Fig. 1E). When
normalised, no differences were observed between healthy do-
nors and patients with liver cirrhosis (71.1 ± 21.3% vs. 75.0 ± 19.6,
p = 0.5147 [Fig. 1F]). However, the decrease observed between
Child-Pugh A and C was confirmed (77.4 ± 19.9 % (A) vs. 71.8 ±
15.9 % (B) vs. 56.9 ± 18.3 % (C); p >0.9999, 0.0919, 0.0038 (A vs. B,
B vs. C, and A vs. C, respectively)]. With TM, the peak height was
significantly increased in patients with liver cirrhosis compared
with healthy donors (168.7 ± 62.9 nM vs. 131.7 ± 62.7 nM; p =
0.0011), but no differences were noted between Child-Pugh
categories (162.7 ± 65.5 nM [A] vs. 177.4 ± 50.5 nM [B] vs. 149.2
± 54.2 nM [C]; p = 0.1030, >0.9999, >0.9999 [A vs. B, B vs. C and A
vs. C]) (Fig. 1G). This resulted in a significantly increased peak
height ratio in patients with liver cirrhosis compared with
healthy donors (0.76 ± 0.17 vs. 0.69 ± 0.15; p = 0.0004) and inJHEP Reports 2020Child-Pugh B and C compared with A (0.71 ± 0.17 [A] vs. 0.89 ±
0.14 [B] vs. 0.94 ± 0.07 [C]; p <0.0001, 0.7419, <0.0001 [A vs. B, B
vs. C and A vs. C, respectively]) (Fig. 1H).
The velocity index was already significantly increased
without TM in patients with liver cirrhosis compared with
healthy donors (146.0 ± 74.9 nM/min vs. 97.1 ± 47.4 nM/min; p
<0.0001) (Fig. 1I). It increased significantly from Child-Pugh A to
B (141.3 ± 74.1 nM/min [A] vs. 182.2 ± 68.2 nM/min [B] vs. 143.2 ±
91.9 nM/min [C]; p = 0.0222, >0.999, 0.999 [A vs. B, B vs. C and A
vs. C, respectively]) as well. Using normalised data, similar re-
sults were obtained (59.9 ± 30.0 [healthy donors] vs. 81.6 ± 38.2 %
[cirrhosis]; 75.9 ± 37.9% [A] vs. 102.4 ± 35.5 % [B] vs. 86.2 ± 40.5 %
[C]; p = 0.0003, 0.0056, 0.5426, >0.9999 [healthy donors vs. pa-
tients with cirrhosis, A vs. B, B vs. C, and A vs. C, respectively] [Fig.
1J]). Addition of TM seems to have a greater impact on velocity
index in patients with liver cirrhosis compared with healthy
donors (velocity index ratio: 1.02 ± 0.20 [healthy donors] vs. 0.89
± 0.22 % [cirrhosis]; 0.86 ± 0.23 [A] vs. 0.92 ± 0.17 % [B] vs. 0.93 ±
0.12 % [C]; p <0.0001, 0.0179, >0.9999, 0.3180 [healthy donors vs.
patients with liver cirrhosis, A vs. B, B vs. C, and A vs. C, respec-
tively] [Fig. 1L]).
Thrombomodulin-mediated inhibition and velocity index
without thrombomodulin according to MELD scores
The results of absolute and normalised ETPwithout TM,
TM-mediated inhibition, and velocity indexwithout TM according
to MELD score are presented in Fig. 2. The absolute and nor-
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Fig. 2. Thrombin generation according to MELD score. TM-mediated inhi-
bition of ETP, velocity indexwithout TM, and velocity indexwithout TM normalised
according to MELD score. Results of linear regression are presented here
(p values for differences of the slope than 0, R2; lines represent the linear
regression line). ETP, endogenous thrombin potential; MELD, model for end-
stage liver disease; NORM., normalized; TM, thrombomodulin; VI, velocity
index.score that was much lower than expected (slope significantly
different than 0 [p <0.0001]; R2 = 0.1024 and 0.1272, respectively)
(Fig. 2A, B). The absolute and normalised velocity indexwithout TM
was not correlated with MELD score (slope not significantly
different than 0 [p = 0.0515 and 0.1543], R2 = 0.0149 and 0.0080)
(Fig. 2C and 2D). The TM-mediated inhibition (Fig. 2E) had an
inverse linear relation to MELD score, which was of much better
quality than for ETPwithout TM (slope very highly significantly
different than 0 (p <0.0001) and R2 = 0.2149). This indicates an
increasing prothrombotic state with increasing cirrhosis stage.ETPwithout TM, Thrombomodulin-mediated inhibition, and
velocity index according to liver dysfunction biomarkers
The results of absolute and normalised ETPwithout TM, the absolute
and relative velocity indexwithout TM, and TM-mediated inhibition
according to liver dysfunction biomarkers are presented in Fig. 3.
The absolute ETPwithout TM had a direct relation to TP (Fig. 3A) and
factor V activity (Fig. 3D), indirect to INR (Fig. 3B), aPTT (Fig. 3C),
and a quadratic relation to total bilirubin (Fig. 3F) (slopes
significantly different than 0 [p <0.0001, 0.0070, <0.0001,
<0.0001, respectively; no p value for the total bilirubin because
the relation was quadratic], R2 = 0.0553, 0.0321, 0.0614, 0.0660,
0.0681). No correlation was observed with albumin (p = 0.1945,
R2 = 0.0066; Fig. 3E). Similar results were observed using nor-
malised values (Fig. 3G–L). However, the quality of the relationJHEP Reports 2020between these biomarkers and ETP was much lower than ex-
pected, considering the use of these biomarkers as bleeding risk
biomarkers. Moreover, the velocity indexwithout TM had an inverse
relation to PT (Fig. 4A), factor V activity (Fig. 4D), albumin
(Fig. 4E), a direct relation to INR (Fig. 4B), aPTT (Fig. 4C), and a
quadratic relation to total bilirubin (Fig. 4F) (all slopes signifi-
cantly different than 0: p <0.0001 [PT, factor V activity, albumin],
0.0103 [INR], 0.0002 [aPTT]; no p value for total bilirubin, which
was assessed by quadratic functions due to their graphical
appearance, R2 = 0.0767 [PT], 0.2611 [factor V activity], 0.1020
[albumin], 0.0253 [INR], 0.0577 [aPTT], 0.0989 [total bilirubin]).
The results obtained with normalised values of velocity
indexwithout TM were very slightly better than those of absolute
values (Fig. 4G–L). Therefore, the velocity indexwithout TM
increases with decreasing PT (expressed in percent), factor V
activity as well as albumin and with increasing INR, aPTT, and
total bilirubin, indicating an increasing prothrombotic state with
increasing disturbances of these parameters, contradicting the
results observed for ETPwithout TM.
The TM-mediated inhibition had a good direct linear relation
to PT (Fig. 4M), factor V activity (Fig. 4P), and albumin (Fig. 4Q)
and a good inverse linear relation to INR (Fig. 4N) (all slopes very
highly significantly different than 0 [p <0.0001], R2 = 0.4130 (PT),
0.4722 (factor V activity), 0.2915 (albumin), 0.3431 (INR)). This
indicates an increasing prothrombotic state with decreasing PT,
factor V activity, and albumin and with increasing INR. Due to
their graphical appearances, the relations between TM-mediated
inhibition and aPTT (Fig. 4O) and total bilirubin (Fig. 4R) were
analysed using quadratic functions. The TM-mediated inhibition
had a good quadratic relation to aPTT and total bilirubin (R2 =
0.3205 and 0.2709, respectively). This indicates an increasing
prothrombotic state with increasing aPTT and total bilirubin.Discussion
The aim of our work was to evaluate the relationship between
liver dysfunction biomarkers and thrombin generation. First,
using a fully automated, standardised, and normalised novel
assay, we confirmed previous observations obtained with the
calibrated automated thrombogram system on thrombin gener-
ation in patients with liver cirrhosis (Fig. 1). Indeed, we observed
a relatively preserved thrombin generation without TM. Of note,
even though ETPwithout TM was only slightly decreased and the
peak height similar in patients with liver cirrhosis compared
with healthy donors, these parameters tended to decrease with
increasing cirrhosis severity. This could indicate a slight decrease
of the procoagulant potential by itself which, however, appears
to be compensated by an increased thrombin generation velocity.
In presence of TM, however, we observed increased thrombin
generation in patients with liver cirrhosis compared with healthy
donors. This indicates the presence of an acquired protein C
resistance and a prothrombotic state in these patients.1,2,5,7
Moreover, we confirm that such a prothrombotic state in-
creases with cirrhosis severity, as assessed by Child-Pugh2,5 or
MELD4,6 scores (Figs. 1 and 2). For example, ETPwith TM (Fig. 1C),
the peak height ratio (Fig. 1H), and the velocity indexwithout TM
(Fig. 1I) increased and the TM-mediated inhibition (Fig. 1D)
decreased significantly from Child-Pugh A to B. Additionally, the
MELD score showed an inverse relation with TM-mediated in-
hibition (Fig. 2E). In sum, the novel assay employed in this study
confirms a prothrombotic state in patients with liver cirrhosis,
which worsens with increasing liver dysfunction.5vol. 2 j 100120
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Fig. 3. ETPwithout TM and normalised ETPwithout TM according to various biomarkers of cirrhosis severity. ETPwithout TM and normalised ETPwithout TM according
to PT, INR, aPTT, factor V activity, albumin, and total bilirubin. Results of linear regressions (p values for differences of the slope than 0, R2; lines represent the
linear regression lines), or nonlinear regressions (R2; lines represent the nonlinear regression lines). aPTT, activated partial thromboplastin time; ETP, endogenous
thrombin potential; INR, international normalised ratio; NORM., normalized; PT, prothrombin time.
Research articleAlthough a prothrombotic shift of the haemostatic balance
has been demonstrated in patients with liver cirrhosis, little is
known about the relation between liver dysfunction biomarkers
and the haemostatic profile, except for a single study of Gatt
et al.7 that reported an increasing prothrombotic profile with
increasing INR. In fact, liver dysfunction biomarkers continue to
be commonly considered as markers of increased bleeding risk in
patients with liver cirrhosis in clinical practice.14–18 In this study,
we evaluated thrombin generation using a fully automated
thrombin generation assay in 260 patients with liver cirrhosis
and compared it with liver dysfunction biomarkers and cirrhosis
stage.
We demonstrated that prolonged PT/INR and aPTT and
decreasing factor V activity are linked to an increasingJHEP Reports 2020prothrombotic shift in patients with liver cirrhosis (Figs. 3 and 4).
Indeed, the relation between ETPwithout TM and the coagulation
assays was much lower than expected. Moreover, the relation
between the velocity indexwithout TM and the TM-mediated in-
hibition and these coagulation assays indicates an increasing
prothrombotic state in these patients. These coagulation assays
have been reported to be only poorly or not at all correlated with
the occurrence of bleeding in patients with cirrhosis.24–26 Our
results explain the absence of correlation between these bio-
markers and the bleeding risk. Therefore, and counterintuitively,
a patient with liver cirrhosis with a prolonged PT and/or aPTT
appears to be at increased risk of venous thromboembolism.
This contradicts the rather widespread clinical practice, in
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Fig. 4. TM-mediated inhibition of ETP, velocity indexwithout TM and normalised velocity indexwithout TM according to various biomarkers of cirrhosis
severity. TM-mediated inhibition of ETP, velocity indexwithout TM, and normalised velocity indexwithout TM according to PT, INR, aPTT, factor V activity, albumin, and
total bilirubin. Results of linear regressions (p values for differences of the slope than 0, R2; lines represent the linear regression lines), or nonlinear regressions
(R2; lines represent the nonlinear regression lines). aPTT, activated partial thromboplastin time; ETP, endogenous thrombin potential; INR, international
normalised ratio; PT, prothrombin time; VI, velocity index.
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Research articlepatients with liver cirrhosis using PT/INR and aPTT. This leads to
a mismanagement of patients with liver cirrhosis, with with-
drawal of prophylactic anticoagulation14,15,27 or administration
of unnecessary blood product transfusion,28–30 potentially
increasing their thrombotic risk and complication rate. Based on
our results, we should advise physicians to stop measuring
these parameters in patients with liver cirrhosis for evaluating
haemorrhagic risk and refrain from correcting these laboratory
parameters with prothrombotic drugs.
In this study, we also demonstrate that increasing total bili-
rubin is associated with an increasing prothrombotic profile
(Figs. 3 and 4). Moreover, we confirm previous observations
reporting an increasing prothrombotic profile with increasing
cirrhosis severity2,4–6 (see above). Similar to PT/INR and aPTT,
total bilirubin and cirrhosis severity are included in several
bleeding risk assessment scores.16–18 Based on our results, the
inclusion of liver dysfunction biomarkers within bleeding
risk assessment scores appears inadequate and should be
re-evaluated.
The presence of liver dysfunction parameters in bleeding risk
assessment scores is very likely due to their indirect relation to
gastrointestinal haemodynamic changes (e.g. portal hyperten-
sion) associated with advanced liver cirrhosis, which leads to an
increased gastrointestinal bleeding risk (e.g. due to rupture of
oesophageal varices). Indeed, the prevalence of bleeding from
oesophageal varices is increased in decompensated liver disease.
However, as demonstrated here, liver dysfunction parameters
are in fact markers of a thrombotic risk and, therefore, are
inadequate for the purpose of identifying a bleeding risk linked
to haemostatic causes. Alternative biomarkers, either specific for
gastrointestinal haemodynamic changes or identifying sub-
groups of patients with liver cirrhosis with a prohaemorrhagic
profile, should be evaluated and should substitute ‘classical’ liver
dysfunction biomarkers. This would prevent falsely highlighting
the above-mentioned biomarkers as indicators of bleeding risk,
eventually improving the quality of the bleeding risk assessment
scores.
The observed relation between total bilirubin and a pro-
thrombotic profile is likely an epiphenomenon related to the
severity of the liver dysfunction. However, some published data
support a direct association between bilirubin and hypercoagu-
lability.31,32 For instance, thrombin generation has been reported
to increase with bilirubin levels up to a concentration of 211
lmol/L in spiking experiments.33 All bilirubin values observed in
our study were lower than this threshold. Therefore, bilirubin
could play a direct role in the increasing thrombin generation
detected in our population. In contrast, a protective role of bili-
rubin has also been described,34 which could be due to its
antioxidant effect.35 Of note, further increase of bilirubin con-
centrations over 211 lmol/L in spiking experiments led to a
decline of thrombin generation.33 Based on our results and the
published evidence, we postulate that the directly proportional
relation between total bilirubin and prothrombotic profile
observed in this study is most likely due to the correlation of
total bilirubin with the degree of liver dysfunction severity in
cirrhosis. However, bilirubin could also play a direct procoagu-
lant role in the range of total bilirubin levels observed in our
population.33
We describe here an indirect relation between albumin and a
prothrombotic haemostatic profile in patients with liver cirrhosis
(Figs. 3E, K and 4E, K, Q). Different studies showed that elevated
INR,36 low albumin,36,37 and elevated bilirubin36 are risk factorsJHEP Reports 2020for the development of portal vein thrombosis. Our results
demonstrate that this is most likely explained by the fact that
alterations of PT/INR, aPTT, and albumin36,37 reflect an intrinsic
prothrombotic profile more than just altered haemodynamic
factors. Thus, biomarkers reflecting liver synthetic dysfunction
should be recognised as indicators of a procoagulant state in liver
cirrhosis. Of note, a direct antiplatelet effect of albumin via the
inhibition of NADPH oxidase 2 and anti-oxidative effect has been
postulated.37 An anti-oxidative effect could also influence coag-
ulation and the prothrombotic haemostatic profile.8 Therefore,
the relation between albumin levels and procoagulant state in
patients with liver cirrhosis could be based not only on its
relation to cirrhosis severity but also to a direct pathophysiologic
role of albumin in haemostasis.
Our study has limitations. First, we investigated only coagu-
lation and not primary haemostasis or fibrinolysis. However,
coagulation is the most important determinant of the haemo-
static balance in patients with liver cirrhosis, and thrombin
generation without and with TM is a well-accepted approach for
assessing the coagulation potential in patients with liver
cirrhosis. Of note, the platelet count seems not to be predictive
for either spontaneous or post-procedural bleeding complica-
tions in patients with liver cirrhosis.38–40 This is likely due to the
‘rebalanced’ primary haemostasis by hyperactive platelets8,40
and increased von Willebrand factor levels.8 Moreover, there is
no generally accepted gold standard for the analysis of primary
haemostasis and fibrinolysis in patients with liver cirrhosis. For
these reasons, in the present study we focused on thrombin
generation. Second, although this study on thrombin generation
in patients with liver cirrhosis is, to the best of our knowledge,
the largest published yet, the number of included patients was
insufficient to perform reliable subgroup analyses between ae-
tiologies. Indeed, haemostatic differences were described across
the different cirrhosis aetiologies.8 The relation between liver
dysfunction biomarkers and the prothrombotic state could be
different according to cirrhosis aetiology. Therefore, larger
studies are required in order to identify potential differences in
the relation between liver dysfunction biomarkers and thrombin
generation for diverse cirrhosis aetiologies. Third, the healthy
and the cirrhotic cohorts are not balanced for age and sex, with
younger and more female subjects in the healthy cohort. How-
ever, the focus of this study is not the comparison between
healthy donors and patients with cirrhosis, but the comparison
between groups with increasing degrees of liver dysfunction.
While some differences can be seen in the thrombin generation
parameters between males and females of the healthy popula-
tion (Fig. S1), previous studies observed no differences between
sexes.41 Moreover, a higher percentage of males in the healthy
population would actually increase the differences observed
between healthy subjects and patients with liver cirrhosis. No
clear tendency for clinically significant changes of thrombin
generation parameters with increasing age was observed in the
healthy population (Fig. S2) and previous studies concluded that
the changes of thrombin generation parameters with age were
too weak to be of importance.41,42 Therefore, the imbalance
observed between the 2 populations studied is not expected to
influence the presented results.
In conclusion, we demonstrate an increasing prothrombotic
profile correlating with worsening alterations of liver dysfunc-
tion biomarkers in patients with liver cirrhosis. In particular,
prolonged PT/INR and aPTT and decreased factor V activity are
related to an increasing thrombotic and not bleeding risk. These8vol. 2 j 100120
parameters should not be used to assess bleeding risk of patients
with liver cirrhosis. Alternative biomarkers for bleeding riskJHEP Reports 2020assessment in patients with liver cirrhosis need to be identified
and investigated.Abbreviations
aPTT, activated partial thromboplastin time; ETP, endogenous thrombin
potential; INR, international normalised ratio; MELD, model for end-stage
liver disease; PFP, platelet-free plasma; PT, prothrombin time; NASH, non-
alcoholic steatohepatitis; TM, thrombomodulin; VTE, venous
thromboembolism.
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